Beclometasone dipropionate showed no clear difference in clinical response at 8 weeks compared with mesalazine (low certainty).
It is very uncertain whether beclometasone dipropionate changes maintenance of clinical response at 12 weeks compared with mesalazine (very low certainty).
Tacrolimus showed no clear difference in clinical improvement compared with beclometasone (low certainty).
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
Tacrolimus showed no clear difference in clinical remission compared with beclometasone (low certainty).